YL Biologics Reports the NDA Submission of YLB217 (biosimilar product of long-acting erythropoiesis stimulating agent Nesp)
Shots:
- YLB reported the NDA filing of YLB217- a biosimilar product of long-acting erythropoiesis-stimulating agent Nesp- which YLB solely developed- was executed through Yoshindo
- On Sept 08- 2017- YLB signed a technology transfer agreement with CJ Healthcare- including exclusive development and marketing rights for Nesp biosimilar and started domestic development with the sponsorship of Yoshindo
- In Jan’2019- YLB has conducted a P-III study that assesses YLB217 in 136 patients with renal anemia at 25 centers in Japan. Based on this- Yoshindo submitted a manufacturing and marketing approval application in Japan
Ref: YL Biologics | Image: YL Biologics
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
